PTN Stock Analysis: Buy, Sell, or Hold?
$10.60
-0.61 (-5.44%)
▼
5d:
-10.7%
30d:
-28.75%
90d:
-46.6%
WAIT
LOW Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When PTN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PTN is down 10.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PTN is down 10.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PTN is currently trading at $10.60, which is considered oversold relative to its 30-day fair value range of $12.33 to $14.77.
Technical Outlook: Technically, PTN is in a downtrend. The price is currently testing key support at $13.09. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $53.50 (+377.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PTN is in a downtrend. The price is currently testing key support at $13.09. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $53.50 (+377.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$12.33 -
$14.77
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.4%)
- BULLISH: Trading 377.3% below Wall St target ($53.50)
- WARNING: Recommendation downgraded due to -10.7% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$12.33 -
$14.77
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$13.09
Resistance Level
$14.88
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.61
Wall Street Target
$53.50
(+377.3%)
Revenue Growth (YoY)
-80.1%
Profit Margin
-48.5%
Share & Embed Analysis
Last updated: June 24, 2026 4:05 PM ET
Data refreshes hourly during market hours. Next update: 5:05 PM
Data refreshes hourly during market hours. Next update: 5:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PTN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 61 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 58 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 61 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 58 HOLD |